Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EBIT (2020 - 2025)

Ovid Therapeutics' EBIT history spans 6 years, with the latest figure at -$12.3 million for Q4 2025.

  • For Q4 2025, EBIT fell 14.65% year-over-year to -$12.3 million; the TTM value through Dec 2025 reached -$42.4 million, up 31.42%, while the annual FY2025 figure was -$42.4 million, 31.42% up from the prior year.
  • EBIT reached -$12.3 million in Q4 2025 per OVID's latest filing, up from -$12.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $176.6 million in Q1 2021 to a low of -$26.4 million in Q4 2021.
  • Average EBIT over 5 years is -$4.7 million, with a median of -$13.0 million recorded in 2022.
  • Peak YoY movement for EBIT: skyrocketed 969.98% in 2021, then tumbled 109.21% in 2022.
  • A 5-year view of EBIT shows it stood at -$26.4 million in 2021, then skyrocketed by 53.81% to -$12.2 million in 2022, then crashed by 49.41% to -$18.2 million in 2023, then surged by 41.05% to -$10.7 million in 2024, then fell by 14.65% to -$12.3 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's EBIT are -$12.3 million (Q4 2025), -$12.5 million (Q3 2025), and -$5.1 million (Q2 2025).